Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues
نویسندگان
چکیده
منابع مشابه
A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
Accurate and precise potency determination by manufacturers of different types of factor VIII product (plasma-derived and recombinant FVIII [rFVIII]) is vital to clinicians and patients using FVIII concentrates. A separate, but related, requirement is ascertaining the FVIII activity levels in clinical samples for diagnosing and treating hemophilia A. The one-stage clotting assay (OSA) and the c...
متن کاملPathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
Pathogenic antibodies targeting coagulation factors usually are clinically significant because they inhibit function. Circulating anticoagulants were recognized as early as 1906 ([1], cited in [2]). They interfere with the coagulation of normal blood as well as that of the patient, which is the basis of the classical mixing study. Circulating anticoagulants inhibiting factor (F)VIII and factor ...
متن کاملFACTOR V AND VIII INHIBITOR IN PATIENTS WITH COMBINED FACTOR V AND VIII DEFICIENCY
Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...
متن کاملDiscrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype.
UNLABELLED Severity of bleeding phenotype in hemophilia A (HA) depends on the underlying mutation in the F8 gene and, ultimately, on the concentration and functional integrity of the factor VIII (FVIII) protein in circulating plasma. Initial diagnosis for HA and monitoring of treatment is typically performed by measuring of FVIII activity by either one-stage assay or chromogenic assay. We revie...
متن کاملChromogenic Factor IX Assay for Clinical Use
A chromogenic factor IX assay is developed which requires only two timedependent steps. Diluted plasma is mixed with a reagent containing factors VIII and X. The reaction is started by addition of a reagent containing factor XI", thrombin, CaCl2, and phospholipids. Then factor XIu activates factor IX if present, thrombin activates factor VIII, and subsequently the complete factor X activating c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haemophilia
سال: 2016
ISSN: 1351-8216
DOI: 10.1111/hae.13012